Literature DB >> 14966135

Cholesterol-independent interactions with CD47 enhance alphavbeta3 avidity.

John F McDonald1, Alex Zheleznyak, William A Frazier.   

Abstract

Expression in OV10 cells of either wild-type CD47 or its extracellular IgV domain linked to a glycosylphosphatidylinositol anchor-(IgV-GPI) enhanced ligand-induced alpha(v)beta(3) activation as detected by the binding of LIBS1 and LIBS6 mAbs. The amplitude of LIBS binding was greater with both CD47 and IgV-GPI expression, indicating an increase in the population of "activable" integrin molecules. Expression of either CD47 species also increased alpha(v)beta(3)-mediated adhesion to vitronectin, and to surfaces coated with the anti-beta(3) antibody AP3, because of enhanced clustering of alpha(v)beta(3) as confirmed by chemical cross-linking. Cholesterol depletion with methyl-beta-cyclodextrin did not prevent the increase in anti-LIBS binding, but reduced cell adhesion to vitronectin and AP3. However, cells expressing CD47 were partially insulated against this disruption, and IgV-GPI was even more effective. Both CD47 and IgV-GPI were found in cholesterol-rich rafts prepared in the absence of detergent, but only CD47 could recruit alpha(v)beta(3) and its associated signaling molecules to these domains. Thus CD47-alpha(v)beta(3) complexes in cholesterol-rich raft domains appear to engage in G(i)-dependent signaling whereas CD47-alpha(v)beta(3) interactions that lead to integrin clustering are also detergent resistant, but are insensitive to cholesterol depletion and do not require the transmembrane region of CD47.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966135     DOI: 10.1074/jbc.M312782200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  CD47-dependent molecular mechanisms of blood outgrowth endothelial cell attachment on cholesterol-modified polyurethane.

Authors:  Masako Ueda; Ivan S Alferiev; Stacey B Simons; Robert P Hebbel; Robert J Levy; Stanley J Stachelek
Journal:  Biomaterials       Date:  2010-06-09       Impact factor: 12.479

Review 2.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 3.  CD47: a new target in cardiovascular therapy.

Authors:  Jeff S Isenberg; David D Roberts; William A Frazier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-10       Impact factor: 8.311

Review 4.  CD47 signaling pathways controlling cellular differentiation and responses to stress.

Authors:  David R Soto-Pantoja; Sukhbir Kaur; David D Roberts
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-02-24       Impact factor: 8.250

5.  Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways.

Authors:  Anat Erdreich-Epstein; Linda B Tran; Orla T Cox; Elaine Y Huang; Walter E Laug; Hiroyuki Shimada; Melissa Millard
Journal:  Blood       Date:  2005-02-10       Impact factor: 22.113

6.  Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.

Authors:  Zhiyuan Lv; Zhen Bian; Lei Shi; Shuo Niu; Binh Ha; Alexandra Tremblay; Liangwei Li; Xiugen Zhang; John Paluszynski; Ming Liu; Ke Zen; Yuan Liu
Journal:  J Immunol       Date:  2015-06-17       Impact factor: 5.422

7.  Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation.

Authors:  Laura A Maile; Lee B Allen; Christopher F Hanzaker; Katherine A Gollahon; Paul Dunbar; David R Clemmons
Journal:  Exp Diabetes Res       Date:  2010-06-20

8.  CD47 regulates bone mass and tumor metastasis to bone.

Authors:  Ozge Uluçkan; Stephanie N Becker; Hongju Deng; Wei Zou; Julie L Prior; David Piwnica-Worms; William A Frazier; Katherine N Weilbaecher
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

9.  Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment.

Authors:  Sukhbir Kaur; Kyle V Cicalese; Rajdeep Bannerjee; David D Roberts
Journal:  Antib Ther       Date:  2020-08-08

10.  Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells.

Authors:  Felicia Cao; Phuong Nguyen; Bangxing Hong; Christopher DeRenzo; Nino C Rainusso; Tania Rodriguez Cruz; Meng-Fen Wu; Hao Liu; Xiao-Tong Song; Masataka Suzuki; Lisa L Wang; Jason T Yustein; Stephen Gottschalk
Journal:  Adv Cell Gene Ther       Date:  2020-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.